ReviewJournal of psychiatry & neuroscience : JPN2003
Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.
Review in Journal of psychiatry & neuroscience : JPN, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 89 citations in OpenAlex.
- Trial
- Corticosterone antagonist or TrkB agonist attenuates schizophrenia-like behavior in a mouse model combiningiScience · 2022Article
- Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia.Scientific reports · 2021Article
- Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property.Frontiers in pharmacology · 2021Article
- Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?Lipids in health and disease · 2020Review
- Role of SREBPs in Liver Diseases: A Mini-review.Journal of clinical and translational hepatology · 2018Review
- Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies.Frontiers in neuroscience · 2016Review
- Multiple Targeting Approaches on Histamine H3 Receptor Antagonists.Frontiers in neuroscience · 2016Review
- Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2015Article
- What does schizophrenia teach us about antipsychotics?Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2015Review
- Antipsychotic dosing: found in translation.Journal of psychiatry & neuroscience : JPN · 2014Review
- Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification.Schizophrenia bulletin · 2013Article
- Arrestin-dependent but G-protein coupled receptor kinase-independent uncoupling of D2-dopamine receptors.Journal of neurochemistry · 2013Article
- Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis.Journal of research in pharmacy practice · 2013Article
- Plasma membrane compartmentalization of D2 dopamine receptors.The Journal of biological chemistry · 2013Article
- Comparative extrapyramidal effects of Rauwolfia vomitoria, chlorpromazine and reserpine in mice.Journal of natural medicines · 2013Article
- Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex.Psychopharmacology · 2012Article
- Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions.Journal of neurochemistry · 2012Article
- D(2)-Dopamine receptors target regulator of G protein signaling 9-2 to detergent-resistant membrane fractions.Journal of neurochemistry · 2012Article
- Sedative load among community-dwelling people aged 75 years and older: a population-based study.Drugs & aging · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of a number of new antipsychotics in the last decade has generated considerable excitement regarding the treatment of schizophrenia and related psychotic conditions. Clinically, it has produced changing expectations regarding treatment outcome, while academically it has encouraged a re-evaluation and expansion of theories of the pathophysiology of schizophrenia and antipsychotic activity. In this review, the development of antipsychotics is traced, beginning with chlorpromazine's introduction in the early 1950s, and followed to the present. Despite 50 years of use and a plethora of antipsychotics available worldwide, our conceptualization of their major mode of action remains essentially unchanged. It was shortly after their development that attention turned to the importance of dopamine, and in particular the dopamine D2 receptor. Current thinking has elaborated on this model, with serotonin and glutamate receiving the greatest attention most recently, but D2 antagonism remains the sine qua non of antipsychotic activity. Although the notion of "atypical" remains somewhat of a moving target, we do have at our disposal a new generation of antipsychotics that reflect a different clinical profile from their conventional counterparts. The precise degree of these differences and the underlying mechanisms remain unclear, however. The direction new antipsychotic development takes will undoubtedly hinge on answers to these questions.
Indexed as
Identifiers
12921222PMC165792W1550186761What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.